136 related articles for article (PubMed ID: 22795584)
1. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
Ji JH; ; Yun T; Kim SB; Kang JH; Park JC; Cho IS; Sohn CH; Heo DS; Jang JS; Shin SW; Hwang DW; Sun JM; Park K; Ahn MJ
Eur J Cancer; 2012 Nov; 48(17):3198-204. PubMed ID: 22795584
[TBL] [Abstract][Full Text] [Related]
2. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Chua DT; Sham JS; Au GK
Oral Oncol; 2005 Jul; 41(6):589-95. PubMed ID: 15975521
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
5. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ
Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
[TBL] [Abstract][Full Text] [Related]
10. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer.
Kim JY; Do YR; Park KU; Kim MK; Lee KH; Bae SH; Ryoo HM; Baek JH; Song HS
Cancer Chemother Pharmacol; 2010 May; 66(1):31-6. PubMed ID: 19763571
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
12. A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer.
Fahlke J; Ridwelski K; Schmidt C; Hribaschek K; Stuebs P; Kettner E; Quietzsch D; Assmann M; Deist T; Keilholz U; Lippert H
Chemotherapy; 2007; 53(6):454-60. PubMed ID: 17957099
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
[TBL] [Abstract][Full Text] [Related]
15. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Tanaka T; Fujita H; Sueyoshi S; Tanaka Y; Sasahara H; Mori N; Nagano T; Yamana H; Shirouzu K
Chemotherapy; 2007; 53(6):449-53. PubMed ID: 17952006
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
[TBL] [Abstract][Full Text] [Related]
17. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
18. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
19. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
[TBL] [Abstract][Full Text] [Related]
20. Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Chen SZ; Chen XM; Ding Y; Wang XC; Zhang F; Mo KL
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1114-8. PubMed ID: 21764676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]